Short answer
Insulet Corporation (PODD) filed its Q1 2025 10-Q quarterly report on May 9, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $569M (up 28.8% year over year) with net income of $35M.
Q1 2025 key financials · XBRL
- Revenue
- $569M
- +28.8% YoY
- Net income
- $35M
- −31.3% YoY
- Operating margin
- 15.6%
- Gross margin
- 71.9%
- EPS (diluted)
- $0.50
- −31.5% YoY
Source: XBRL data from the Insulet Corporation (PODD) Q1 2025 10-Q on SEC EDGAR. USD.
Insulet Corporation Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Continued supply chain disruptions impacting production capacity and inventory levels
- Exposure to competitive threats from new insulin delivery technologies
- Legal risk from ongoing intellectual property litigation with key competitor
- Market risk from fluctuating foreign currency exchange rates affecting international sales
- Liquidity risk due to $500M debt maturing in 2026 with covenant restrictions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Insulet Corporation quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.